Trial Profile
Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors SymBio Pharmaceuticals
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 26 Jun 2015 According to a SymBio Pharmaceuticals media release, the company completion of this phase I study for oral rigosertib (SyB C-1101).